Pub Date : 2026-02-12DOI: 10.1016/s2213-2600(26)00006-8
Clarus Leung, Don D Sin
No Abstract
没有抽象的
{"title":"Add-on LAMA therapy in asthma: an underused strategy for exacerbation prevention","authors":"Clarus Leung, Don D Sin","doi":"10.1016/s2213-2600(26)00006-8","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00006-8","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"59 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146198401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-12DOI: 10.1016/s2213-2600(25)00457-6
Alberto Papi, Robert A Wise, David J Jackson, Njira Lugogo, Ruchong Chen, Teodora Trasieva, Chidi Obasi, Charlotta Movitz, Jesse Helman, Patricia Salter, Katarzyna Springer, Marco Bondoc, Mihir Shah, Katharine Knappenberger, Karin Bowen, Hitesh Pandya, Ayman Megally, Mehul Patel
<h3>Background</h3>Long-acting muscarinic antagonists (LAMA) can be added to inhaled corticosteroid– (ICS)–long-acting β<sub>2</sub>-agonist (LABA) therapy for inadequately controlled asthma. We aimed to evaluate the efficacy and safety of budesonide–glycopyrronium–formoterol fumarate dihydrate (BGF) versus budesonide–formoterol fumarate dihydrate using Aerosphere co-suspension delivery technology (BFF<sub>A</sub>) and the current suspension formulation (Symbicort, BFF<sub>S</sub>).<h3>Methods</h3>Two multicentre, randomised, double-blind, double-dummy, phase 3 studies (KALOS and LOGOS) recruited participants aged 12–80 years with inadequately-controlled asthma despite daily medium-dose or high-dose ICS–LABA use from across 378 sites in 20 countries (KALOS), and 324 sites in 15 countries (LOGOS). Participants were randomly assigned (1:1:1:1) to BGF 320 μg, 28·8 μg, 10 μg (BGF 28·8); BGF 320 μg, 14·4 μg, 10 μg (BGF 14·4); BFF<sub>A</sub> 320 μg, 10 μg; or BFF<sub>S</sub> 320 μg, 9 μg, twice a day via pressurised metered-dose inhaler for 24–52 weeks. Primary lung function endpoints were change from baseline in FEV<sub>1</sub> area under the curve from 0 h to 3 h (AUC<sub>0–3</sub>) and in morning pre-dose trough FEV<sub>1</sub> from day 1 to week 24 (over 24 weeks; depending on regional health authority guidance). The primary pooled analysis across both studies was annualised severe exacerbations. The efficacy analysis set and safety set included all randomly assigned participants receiving any amount of study treatment but were analysed according to randomly assigned treatment and received treatment, respectively. The KALOS and LOGOS studies are registered with <span><span>ClinicalTrials.gov</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span> (<span><span>NCT04609878</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span> and <span><span>NCT04609904</span><svg aria-label="Opens in new window" focusable="false" height="20" viewbox="0 0 8 8"><path d="M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z"></path></svg></span>, respectively) and are complete.<h3>Findings</h3>Between Dec 15, 2020, and March 21, 2025 (KALOS), and between March 1, 2021, and March 20, 2025 (LOGOS), 8820 participants were recruited and 4311 received treatment (1179 received BGF 28·8, 726 received BGF 14·4, 1210 received BFF<sub>A</sub>, and 1196 received BFF<sub>S</sub>). In each study, the pre-specified multiplicity-adjusted primary endpoints for all regulatory comparisons were met. Least squares mean differences favoured BGF 28·8 for change from baseline in trough FEV<sub>1</sub> and FEV<sub>1</sub> AUC<sub>0–3</sub> across al
{"title":"Budesonide–glycopyrronium–formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials","authors":"Alberto Papi, Robert A Wise, David J Jackson, Njira Lugogo, Ruchong Chen, Teodora Trasieva, Chidi Obasi, Charlotta Movitz, Jesse Helman, Patricia Salter, Katarzyna Springer, Marco Bondoc, Mihir Shah, Katharine Knappenberger, Karin Bowen, Hitesh Pandya, Ayman Megally, Mehul Patel","doi":"10.1016/s2213-2600(25)00457-6","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00457-6","url":null,"abstract":"<h3>Background</h3>Long-acting muscarinic antagonists (LAMA) can be added to inhaled corticosteroid– (ICS)–long-acting β<sub>2</sub>-agonist (LABA) therapy for inadequately controlled asthma. We aimed to evaluate the efficacy and safety of budesonide–glycopyrronium–formoterol fumarate dihydrate (BGF) versus budesonide–formoterol fumarate dihydrate using Aerosphere co-suspension delivery technology (BFF<sub>A</sub>) and the current suspension formulation (Symbicort, BFF<sub>S</sub>).<h3>Methods</h3>Two multicentre, randomised, double-blind, double-dummy, phase 3 studies (KALOS and LOGOS) recruited participants aged 12–80 years with inadequately-controlled asthma despite daily medium-dose or high-dose ICS–LABA use from across 378 sites in 20 countries (KALOS), and 324 sites in 15 countries (LOGOS). Participants were randomly assigned (1:1:1:1) to BGF 320 μg, 28·8 μg, 10 μg (BGF 28·8); BGF 320 μg, 14·4 μg, 10 μg (BGF 14·4); BFF<sub>A</sub> 320 μg, 10 μg; or BFF<sub>S</sub> 320 μg, 9 μg, twice a day via pressurised metered-dose inhaler for 24–52 weeks. Primary lung function endpoints were change from baseline in FEV<sub>1</sub> area under the curve from 0 h to 3 h (AUC<sub>0–3</sub>) and in morning pre-dose trough FEV<sub>1</sub> from day 1 to week 24 (over 24 weeks; depending on regional health authority guidance). The primary pooled analysis across both studies was annualised severe exacerbations. The efficacy analysis set and safety set included all randomly assigned participants receiving any amount of study treatment but were analysed according to randomly assigned treatment and received treatment, respectively. The KALOS and LOGOS studies are registered with <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> (<span><span>NCT04609878</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> and <span><span>NCT04609904</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, respectively) and are complete.<h3>Findings</h3>Between Dec 15, 2020, and March 21, 2025 (KALOS), and between March 1, 2021, and March 20, 2025 (LOGOS), 8820 participants were recruited and 4311 received treatment (1179 received BGF 28·8, 726 received BGF 14·4, 1210 received BFF<sub>A</sub>, and 1196 received BFF<sub>S</sub>). In each study, the pre-specified multiplicity-adjusted primary endpoints for all regulatory comparisons were met. Least squares mean differences favoured BGF 28·8 for change from baseline in trough FEV<sub>1</sub> and FEV<sub>1</sub> AUC<sub>0–3</sub> across al","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"42 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146184518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1016/s2213-2600(25)00370-4
Amy PK Nelson, Nick Dodds, Mohamad Zeina, Alfred Balston, Dominic Giles, William H Seligman, Ashwani Jha, Parashkev Nachev, Julian Thompson
{"title":"Survival effect of prehospital emergency anaesthesia with intubation in risk-stratified patients with major trauma: a causal modelling study","authors":"Amy PK Nelson, Nick Dodds, Mohamad Zeina, Alfred Balston, Dominic Giles, William H Seligman, Ashwani Jha, Parashkev Nachev, Julian Thompson","doi":"10.1016/s2213-2600(25)00370-4","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00370-4","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"543 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1016/s2213-2600(26)00002-0
Amber G den Hollander, Prabath W B Nanayakkara
{"title":"From data to decision: the future of prehospital intubation in major trauma","authors":"Amber G den Hollander, Prabath W B Nanayakkara","doi":"10.1016/s2213-2600(26)00002-0","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00002-0","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"1 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-10DOI: 10.1016/s2213-2600(26)00022-6
Eric Lim
{"title":"JCOG0802 and CALGB140503: the gap between trial design and clinical application","authors":"Eric Lim","doi":"10.1016/s2213-2600(26)00022-6","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00022-6","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"286 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146152716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1016/s2213-2600(26)00016-0
Pierre Goussard, Jacques Janson, Zane Ismail, Ernst Eber, André Gie, Savvas Andronikou
{"title":"Pulmonary hydatid disease in children: a neglected burden hidden in plain sight","authors":"Pierre Goussard, Jacques Janson, Zane Ismail, Ernst Eber, André Gie, Savvas Andronikou","doi":"10.1016/s2213-2600(26)00016-0","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00016-0","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"304 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146134134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1016/s2213-2600(26)00013-5
Ashna Ashesh, Jennfier Furin
{"title":"Tackling the twin crises of tuberculosis and undernutrition","authors":"Ashna Ashesh, Jennfier Furin","doi":"10.1016/s2213-2600(26)00013-5","DOIUrl":"https://doi.org/10.1016/s2213-2600(26)00013-5","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"9 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146134133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fixed PEEP is not lung expansion physiology: reinterpreting the PROTHOR trial","authors":"Carsten Külls, Niloufar Dadashpour, Majid Golestanieraghi","doi":"10.1016/s2213-2600(25)00459-x","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00459-x","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"17 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-03DOI: 10.1016/s2213-2600(25)00437-0
Eric Harbour, Camilla Illidi, James H Hull
{"title":"Breathing in sport: can we make breath work better?","authors":"Eric Harbour, Camilla Illidi, James H Hull","doi":"10.1016/s2213-2600(25)00437-0","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00437-0","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"1 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146109978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：